BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.
BioCryst Pharmaceuticals, Inc.
BioCryst is currently recruiting patients to participate in clinical trials
BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and BCX4208, a PNP inhibitor for the treatment of gout. In addition, BioCryst has two preclinical programs advancing towards IND filings: BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for hereditary angioedema.
To learn more about BioCryst Pharmaceuticals please read the company’s 2011 annual report.
Latest News
May 7, 2012BioCryst Provides Corporate Update and Reports First Quarter 2012 Financial Results
May 1, 2012BioCryst to Present at Two Upcoming Investor Conferences
April 25, 2012BioCryst to Report First Quarter 2012 Financial Results on May 7, 2012
UPCOMING EVENTS
BioCryst to present at JMP Securities Research Conference on May 15, 2012 at 11:30 a.m. PT
BioCryst to present at Bank of America Merrill Lynch Healthcare Conference on May 16, 2012 at 5:00 p.m. PT